請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33774
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 程蘊菁 | |
dc.contributor.author | I-Ching Lee | en |
dc.contributor.author | 李奕慶 | zh_TW |
dc.date.accessioned | 2021-06-13T05:45:55Z | - |
dc.date.available | 2012-10-03 | |
dc.date.copyright | 2011-10-03 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-26 | |
dc.identifier.citation | References
1. Liu, C. C., Wu, W. J., Lee, Y. C. et al.: The prevalence of and risk factors for androgen deficiency in aging Taiwanese men. J Sex Med, 6: 936, 2009 2. Araujo, A. B., O'Donnell, A. B., Brambilla, D. J. et al.: Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab, 89: 5920, 2004 3. Seftel, A.: Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis. Int J Impot Res, 18: 223, 2006 4. L.A.J. Heinemann, T. Z., A. Vermeulen, C. Thiel, W. Hummel: A new 'aging males' symptoms' rating scale. The Aging Male, 2: 105, 1999 5. Heinemann, L. A., Saad, F., Zimmermann, T. et al.: The Aging Males' Symptoms (AMS) scale: update and compilation of international versions. Health Qual Life Outcomes, 1: 15, 2003 6. Kratzik, C. W., Reiter, W. J., Riedl, A. M. et al.: Hormone profiles, body mass index and aging male symptoms: results of the Androx Vienna Municipality study. Aging Male, 7: 188, 2004 7. Basar, M. M., Aydin, G., Mert, H. C. et al.: Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology, 66: 597, 2005 8. Emmelot-Vonk, M. H., Verhaar, H. J., Nakhai-Pour, H. R. et al.: Low testosterone concentrations and the symptoms of testosterone deficiency according to the Androgen Deficiency in Ageing Males (ADAM) and Ageing Males' Symptoms rating scale (AMS) questionnaires. Clin Endocrinol (Oxf), 74: 488, 2011 9. Miwa, Y., Kaneda, T., Yokoyama, O.: Correlation between the Aging Males' Symptoms Scale and sex steroids, gonadotropins, dehydroepiandrosterone sulfate, and growth hormone levels in ambulatory men. J Sex Med, 3: 723, 2006 10. Bhasin, S., Cunningham, G. R., Hayes, F. J. et al.: Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 95: 2536, 2010 11. Chen, C. Y., Wang, W. S., Liu, C. Y. et al.: Reliability and validation of a Chinese version of the Aging Males' Symptoms scale. Psychol Rep, 101: 27, 2007 12. Vermeulen, A., Verdonck, L., Kaufman, J. M.: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab, 84: 3666, 1999 13. Levey, A. S., Bosch, J. P., Lewis, J. B. et al.: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of Internal Medicine, 130: 461, 1999 14. Wang, C., Alexander, G., Berman, N. et al.: Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab, 81: 3578, 1996 15. Barrett-Connor, E., Von Muhlen, D. G., Kritz-Silverstein, D.: Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab, 84: 573, 1999 16. Yamaguchi, K., Ishikawa, T., Chiba, K. et al.: Assessment of possible effects for testosterone replacement therapy in men with symptomatic late-onset hypogonadism. Andrologia, 43: 52, 2011 17. Dickerman, R. D., McConathy, W. J.: Testosterone, vasopressin and depression. Prog Neuropsychopharmacol Biol Psychiatry, 21: 247, 1997 18. Janowsky, J. S., Oviatt, S. K., Orwoll, E. S.: Testosterone influences spatial cognition in older men. Behav Neurosci, 108: 325, 1994 19. Eberhard, J., Stahl, O., Cohn-Cedermark, G. et al.: Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality. J Affect Disord, 122: 260, 2010 20. Giltay, E. J., Haider, A., Saad, F. et al.: C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation. Andrologia, 40: 398, 2008 21. Kaplan, S. A., Johnson-Levonas, A. O., Lin, J. et al.: Elevated high sensitivity C-reactive protein levels in aging men with low testosterone. Aging Male, 13: 108, 2010 22. Denzer, C., Muche, R., Mayer, H. et al.: Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome. J Pediatr Endocrinol Metab, 16: 1225, 2003 23. Rosen, R., Tomer, Y., Carel, R. et al.: Serum 17-beta-estradiol and testosterone levels in asymptomatic hyperuricaemic men. Clin Rheumatol, 13: 219, 1994 24. Akishita, M., Fukai, S., Hashimoto, M. et al.: Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. Hypertens Res, 33: 587, 2010 25. Kaplan, S. A., Lin, J., Johnson-Levonas, A. O. et al.: Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosterone. Aging Male, 13: 40, 2010 26. Makinen, J. I., Perheentupa, A., Irjala, K. et al.: Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis, 197: 688, 2008 27. Stanworth, R. D., Jones, T. H.: Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res, 37: 74, 2009 28. Corona, G., Boddi, V., Balercia, G. et al.: The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med, 7: 1547, 2010 29. Marin, P., Holmang, S., Gustafsson, C. et al.: Androgen treatment of abdominally obese men. Obes Res, 1: 245, 1993 30. Phillips, G. B., Jing, T. Y., Resnick, L. M. et al.: Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens, 11: 699, 1993 31. Basaria, S., Coviello, A. D., Travison, T. G. et al.: Adverse events associated with testosterone administration. N Engl J Med, 363: 109, 2010 32. Hanke, H., Lenz, C., Hess, B. et al.: Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation, 103: 1382, 2001 33. Yue, P., Chatterjee, K., Beale, C. et al.: Testosterone relaxes rabbit coronary arteries and aorta. Circulation, 91: 1154, 1995 34. Kumai, T., Tanaka, M., Watanabe, M. et al.: Elevated tyrosine hydroxylase mRNA levels in the adrenal medulla of spontaneously hypertensive rats. Jpn J Pharmacol, 65: 367, 1994 35. Kumai, T., Tanaka, M., Watanabe, M. et al.: Influence of androgen on tyrosine hydroxylase mRNA in adrenal medulla of spontaneously hypertensive rats. Hypertension, 26: 208, 1995 36. Zukowska-Grojec, Z.: Neuropeptide Y. A novel sympathetic stress hormone and more. Ann N Y Acad Sci, 771: 219, 1995 37. Kienitz, T., Quinkler, M.: Testosterone and blood pressure regulation. Kidney Blood Press Res, 31: 71, 2008 38. Feldman, H. A., Goldstein, I., Hatzichristou, D. G. et al.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol, 151: 54, 1994 39. Fitzgerald, M. P., Link, C. L., Litman, H. J. et al.: Beyond the lower urinary tract: the association of urologic and sexual symptoms with common illnesses. Eur Urol, 52: 407, 2007 40. Somani, B., Khan, S., Donat, R.: Screening for metabolic syndrome and testosterone deficiency in patients with erectile dysfunction: results from the first UK prospective study. BJU Int, 106: 688, 2010 41. Reffelmann, T., Kloner, R. A.: Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag, 2: 447, 2006 42. Holt-Lunstad, J., Birmingham, W., Jones, B. Q.: Is there something unique about marriage? The relative impact of marital status, relationship quality, and network social support on ambulatory blood pressure and mental health. Annals of Behavioral Medicine, 35: 239, 2008 43. Morales, A., Lunenfeld, B.: Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male, 5: 74, 2002 44. Feldman, H. A., Longcope, C., Derby, C. A. et al.: Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab, 87: 589, 2002 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33774 | - |
dc.description.abstract | 前言
男性血液中的睪固酮濃度會隨著年齡而下降,因而產生一些相關症狀。生殖腺官能低下(Hypogonadism)即代表了血液中睪固酮不足的狀況。而晚發性生殖腺官能低下(late-onset hypogonadism, LOH)即表示除了血液中睪固酮濃度不足以外,還加上有相對應的症狀。老年男性症狀量表即用來評估相對應的症狀。之前有一些研究探討了它與血液中睪固酮濃度的相關性,但是結果都很不一致。因此本研究主要目的試探討睪固酮與其相關生物標記和男性老年症狀評量表之相關性。此外,本研究也探討是否有其他因子會干擾此相關性。 方法與研究對象 本研究納入了774位40歲以上,於2008年十一月至2009年十月間至台大醫院接受自費健檢的男性。他們均回答了老年男性症狀評量表,也接受抽血檢測,包含睪固酮在內的多項生化值。睪固酮的絕對值被分為三等分,此外,本研究創造了兩個生物標記,即生物可利用睪固酮比例(bioavailable testosterone ratio, BTR)與游離睪固酮比例(free testosterone ratio, FTR)。本研究的結果即老年男性症狀量表,將其依嚴重度雙切。此外,一些其他重要的變項也一起放入模式中調整。統計使用邏輯斯回歸進行資料分析。 結果 睪固酮會隨著年齡增加而降低(此趨勢的p值小於0.0001)。被三等份的睪固酮與老年男性症狀量表的相關性十分不一致也不穩定。相反的,較高的BTR與FTR產生精神性症狀的危險性較低(BTR調整後的勝算比為0.98, 95%信賴區間 0.97-0.99,FTR調整後勝算比為0.62, 95%信賴區間0.40-0.95)。同樣的,較高的BTR與FTR產生總和症狀的危險性也較低(BTR調整後的勝算比為0.94, 95%信賴區間 0.90-0.98,FTR調整後勝算比為0.25, 95%信賴區間0.08-0.72)。而當使用多項邏輯斯回歸分析時也得到相似的結果。一些重要共變項,如:高血壓、高血脂、高尿酸、婚姻狀態、年紀、與C反應蛋白(CRP)等,與睪固酮並不存在交互作用,其交互作用p值均大於0.05。 討論 由於平均年齡增加,老年已變成一個重要的議題。LOH會使得健康相關的生活品質惡化,因此在無禁忌症且有正確診斷的情況下,可以考慮給補充睪固酮。過去的研究大多以睪固酮的絕對值來分析研究而得到了不一致的結果,因此對LOH的診斷較無幫助。BTR與FTR為兩個相對穩定的生物標記,可代表一段時間內的睪固酮分布,在本研究中它顯示了與老年男性症狀評量表的精神症狀一致且穩定的保護相關性。睪固酮可以穿過腦-血管-障蔽並與腦內的睪固酮受器作用,因此會影響人類的情緒與精神狀況。至於其他的重要共變項則不存在與BTR, FTR的交互作用。 結論 本研究顯示,BTR與FTR與老年男性症狀評量表中的精神領域與總和症狀有保護性的相關性。相反的,睪固酮的絕對值則顯示出不一致且不穩定的相關性。因此,使用BTR與FTR應該可以幫助泌尿科醫師在診斷 LOH並進一步給與治療時更有實用價值。 | zh_TW |
dc.description.abstract | Introduction
Serum testosterone can be classified as sex hormone binding globulin (SHBG)-bound, albumin-bound and free forms. The latter two combined are termed bioavailable testosterone. Testosterone decreases with age and thus causes related symptoms. Hypogonadism indicates the condition of decreased serum testosterone. Late-onset hypogonadism (LOH) has been used to describe hypogonadism in combination with its related symptoms. The crude prevalence is about 12% in Taiwan. Aging males’ symptoms scale (AMS) has been used widely to evaluate symptoms related to hypogonadism. Its association with serum testosterone has been studied with inconsistent conclusions. Our aim is to explore the association between serum testosterone related markers and the symptoms of hypogonadism. In addition, this study also explored other factors which may interfere with the association. Materials and Methods This was a cross-sectional study. A total of 774 men aged 40 years or older were recruited from the self-paid health checkup service at National Taiwan University Hospital (NTUH) from November 2008 to October 2009. All of them completed the AMS and blood sample was collected to determine serum testosterone level along with other biomarkers. Absolute value of testosterone was tertiled and two testosterone-related markers were created, bioavailable and free testosterone ratio (BTR, FTR). The outcome of this study was AMS, and it was dichotomized by severity. Other covariates were also adjusted in the study. Logistic regression and multinomial logistic regression analyses were used for data analysis. Results Testosterone decreased with age (p for trend <0.0001). The association between tertiled testosterone and AMS was inconsistent and unstable. In contrast, higher BTR and FTR showed a decreased risk of developing psychological symptoms (AOR for BTR=0.98, 95% CI=0.97-0.99; AOR for FTR=0.62, 95% CI=0.40-0.95). Higher BTR and FTR were also associated with decreased risks of developing severe overall symptoms (AOR for BTR=0.94, 95% CI=0.90-0.98; AOR for FTR=0.25, 95% CI=0.08-0.72). Similar results were also found by multinomial logistic regression. However, effect modification by some covariates, e.g., hypertension, hyperuricemia, hyperlipidemia, CRP, marital status and age, were not significant. Discussions Lifespan has expanded nowadays so aging has become an important issue. LOH may deteriorate health-related quality of life so testosterone replacement therapy can be considered if correct diagnosis is made, and no contraindication exists. Previous studies used absolute value of testosterone to analyze its association with symptoms, but the conclusions were inconsistent. In our study, BTR and FTR were two stable biomarkers which were consistently associated with psychological AMS. Testosterone can cross the blood-brain-barrier and act on the androgen receptors in the brain. Therefore, decreased testosterone is associated with the development of psychological symptoms. Other covariates were also adjusted in this study. However, none of them significantly modified the association between testosterone related markers and AMS. Conclusions Bioavailable and free testosterone ratios (BTR and FTR) were significantly associated with psychological and total AMS with a protective effect. In contrast, the association between absolute value of testosterone and AMS was inconsistent and unstable. Therefore, BTR and FTR can help urologists in making correct diagnosis of LOH. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T05:45:55Z (GMT). No. of bitstreams: 1 ntu-100-R98846010-1.pdf: 766551 bytes, checksum: b6cd0376e65de5d5eebf1db6b866f031 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 目錄
誌謝 i Abstract ii 中文摘要 v Chapter 1. Introduction 1 1.1 Late-onset hypogonadism 1 1.2 Serum testosterone 1 1.3 Associations between testosterone and hypogonadism related symptoms 2 1.4 Aims 2 Chapter 2. Materials and Methods 4 2.1 Study Population 4 2.2 Evaluation of Hypogonadism 4 2.3 Testosterone Related Markers 5 2.4 Statistical Analyses 5 Chapter 3. Results 7 3.1 Demographic characteristics of study population 7 3.2 Testosterone and related markers 7 3.3 Testosterone and AMS 7 3.4 Effect modification by CRP, hyperlipidemia, hyperuricemia, hypertension, marital status and age 8 Chapter 4. Discussions 12 4.1 Brief findings 12 4.2 Comparisons with previous studies 12 4.3 Effect of potential confounders 12 4.4 The rationale of applying BTR and FTR on diagnosis of late-onset hypogonadism 15 4.5 Clinical implication 15 4.6 Strengths and limitations 16 Chapter 5. Conclusions 18 References 37 圖目錄 Figure 1. Flow chart of this study 19 Figure 2. Distribution of serum testosterone level 20 Figure 3. Distribution of serum bioavailable ratio (BTR) and free testosterone ratio (FTR) 21 Figure 4. Distribution of AMS 22 表目錄 Table 1. Aging males’ symptoms scale- Taiwanese version 23 Table 2. Score range of each domain by symptom severity4 24 Table 3. Characteristics of the Study Participants 25 Table 4. Testosterone distribution trend by age groups 26 Table 5. Association of tertiled testosterone with AMS 27 Table 6. Association of bioavailable and free testosterone ratios with AMS 29 Table 7. Association of bioavailable and free testosterone ratios with AMS (Multinomial) 30 Table 8. Effect modification by CRP on the association between BTR/FTR and AMS 31 Table 9. Effect modification by hypertension on the association between BTR/FTR and AMS 32 Table 10. Effect modification by hyperlipidemia on the association between BTR/FTR and AMS 33 Table 11. Effect modification by hyperuricemia on the association between BTR/FTR and AMS 34 Table 12. Effect modification by marital status on the association between BTR/FTR and AMS 35 Table 13. Effect modification by age on the association between BTR/FTR and AMS 36 | |
dc.language.iso | en | |
dc.title | 睪固酮相關因子與老年男性症狀量表之關連研究 | zh_TW |
dc.title | The Association between Testosterone Related Markers and Aging Males' Symptoms Scale | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 劉詩彬,丘政民,余明暉,季瑋珠 | |
dc.subject.keyword | 睪固酮,生殖腺官能低下,男性更年期,老化,危險因子, | zh_TW |
dc.subject.keyword | Testosterone,Hypogonadism,Andropause,Aging,Risk factor, | en |
dc.relation.page | 40 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-27 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 748.58 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。